16,810 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 16,810 shares of the biopharmaceutical company’s stock, valued at approximately $707,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $686,000. AXQ Capital LP acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at $971,000. Magnetar Financial LLC acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at $285,000. Teacher Retirement System of Texas raised its position in Ultragenyx Pharmaceutical by 20.2% during the 4th quarter. Teacher Retirement System of Texas now owns 24,574 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 4,130 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its stake in shares of Ultragenyx Pharmaceutical by 6.5% in the 4th quarter. Privium Fund Management B.V. now owns 258,380 shares of the biopharmaceutical company’s stock worth $10,870,000 after acquiring an additional 15,868 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $39.18 on Friday. The firm’s fifty day moving average price is $41.88 and its 200 day moving average price is $47.45. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of -6.18 and a beta of 0.67. Ultragenyx Pharmaceutical Inc. has a 12-month low of $37.02 and a 12-month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to analysts’ expectations of $163.23 million. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 6,028 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the transaction, the executive vice president now owns 265,238 shares of the company’s stock, valued at $11,166,519.80. This trade represents a 2.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. This trade represents a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 136,370 shares of company stock worth $5,751,499. Insiders own 5.80% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of several analyst reports. Wedbush reissued a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Canaccord Genuity Group increased their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Wells Fargo & Company increased their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.71.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.